Treatment of chronic heart failure with carvedilol in daily practice:: The SATELLITE survey experience

被引:35
作者
Lainscak, Mitja
Moullet, Christine
Schoen, Norbert
Tendera, Michal
机构
[1] Gen Hosp Murska Sobota, Dept Internal Med, SL-9000 Murska Sobota, Slovenia
[2] Univ Med Berlin, Charite, Dept Cardiol, Div Appl Cachexia Res, Berlin, Germany
[3] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[4] L Warynski Silesian Med Acad, Div Cardiol 3, Katowice, Poland
关键词
beta-blocker; carvedilol; chronic heart failure; efficacy; tolerability;
D O I
10.1016/j.ijcard.2007.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: beta-blockers are well established for treatment of chronic heart failure (CHF). However, the extent of implementation of trial results and guidelines in daily practice remains limited, and information regarding how patients feel is scarce. Methods: In this prospective observational survey of 6 months duration, 531 physicians from 10 countries recruited 3748 beta-blockers untreated patients with CHF. We assessed the efficacy, tolerability and achieved dosage of carvedilol. In addition, patients assessed their wellbeing 3 times: at baseline, after 3 and 6 months of treatment. Results: Carvedilol was started in 3721 patients with CHF (median age 65 years, 60% men). NYHA class, clinical symptoms and signs, vital signs, 5-item well-being rating scale and visual analogue scale improved during the survey. Side effects, mostly fatigue, hypotension, and dizziness, were reported for 6.5% and 5% of patients at 3 and 6 months and carvedilol had to be discontinued in 63 patients. A total of 55 deaths (1.5%) and 520 hospitalisations in 466 patients (13%) were recorded. At 6 months the mean daily dose of carvedilol was 31+/-11 mg; 25 mg/day was prescribed to 35% and 50 mg/day to 26% of patients. Conclusions: Initiation and up-titration of carvedilol in ambulatory care patients with CHF is feasible and safe. Its efficacy and tolerability were at least as good as in clinical trials, while the amelioration of patients' well-being was significant despite sub-optimal dosing. An additional effort should be done by physicians to treat their patients with CHF in daily practice with the recommended beta-blockers at optimal doses. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 30 条
[1]   Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment [J].
Andersson, B ;
Kjörk, E ;
Brunlöf, G .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 104 (03) :257-263
[2]   Improving guideline adherence -: A randomized trial evaluating strategies to increase β-blocker use in heart failure [J].
Ansari, M ;
Shlipak, MG ;
Heidenreich, PA ;
Van Ostaeyen, D ;
Pohl, EC ;
Browner, WS ;
Massie, BM .
CIRCULATION, 2003, 107 (22) :2799-2804
[3]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[4]   Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure - Too many cooks will spoil the broth [J].
Cleland, JGF ;
Clark, AL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (07) :1234-1237
[5]   Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey [J].
Cleland, JGF ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Eastaugh, J ;
Follath, F ;
Freemantle, N ;
Gavazzi, A ;
van Gilst, WH ;
Hobbs, FDR ;
Korewicki, J ;
Madeira, HC ;
Preda, I ;
Swedberg, K ;
Widimsky, J .
LANCET, 2002, 360 (9346) :1631-1639
[6]   The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe - Part 1: patient characteristics and diagnosis [J].
Cleland, JGF ;
Swedberg, K ;
Follath, F ;
Komajda, M ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Gavazzi, A ;
Hobbs, R ;
Korewicki, J ;
Madeira, HC ;
Moiseyev, VS ;
Preda, I ;
van Gilst, WH ;
Widimsky, J ;
Freemantle, N ;
Eastaugh, J ;
Mason, J .
EUROPEAN HEART JOURNAL, 2003, 24 (05) :442-463
[7]   Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390
[8]   Current presentation and management of heart failure in cardiology and internal medicine hospital units: A tale of two worlds - The TEMISTOCLE study [J].
Di Lenarda, A ;
Scherillo, M ;
Maggioni, AP ;
Acquarone, N ;
Ambrosio, GB ;
Annicchiarico, M ;
Bellis, P ;
Bellotti, P ;
De Maria, R ;
Lavecchia, R ;
Lucci, D ;
Mathieu, G ;
Opasich, C ;
Porcu, M ;
Tavazzi, L ;
Cafiero, M .
AMERICAN HEART JOURNAL, 2003, 146 (04)
[9]   FASTTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) [J].
Flather, MD ;
Shibata, MC ;
Coats, AJS ;
Van Veldhuisen, DJ ;
Parkhomenko, A ;
Borbola, J ;
Cohen-Solal, A ;
Dumitrascu, D ;
Ferrari, R ;
Lechat, P ;
Soler-Soler, J ;
Tavazzi, L ;
Spinarova, L ;
Toman, J ;
Böhm, M ;
Anker, SD ;
Thompson, SG ;
Poole-Wilson, PA .
EUROPEAN HEART JOURNAL, 2005, 26 (03) :215-225
[10]   β-Blocker therapy for heart failure outside the clinical trial setting:: Findings of a community-based registry [J].
Franciosa, JA ;
Massie, BM ;
Lukas, MA ;
Nelson, JJ ;
Lottes, S ;
Abraham, WT ;
Fowler, M ;
Gilbert, EM ;
Greenberg, B .
AMERICAN HEART JOURNAL, 2004, 148 (04) :718-726